PDS Biotechnology

Company snapshot

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of T-cell Stimulating Immunotherapies (TSI) based on the Versamune® platform, designed to harness the power of the body's immune system in the fight against cancer.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for PDS Biotechnology. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for PDS Biotechnology.

1. Jun 8, 2026 Clinical update

   U10-02-11-001 — Phase 1

2. Jun 8, 2026 Clinical update

   Combination Treatment of PDS0101 and Pembrolizumab — Phase 3

3. May 23, 2026 Clinical update

   Pembrolizumab (KEYTRUDA®) and PDS0101 — Phase 2

4. Feb 27, 2024 Patent grant

   Stimulation of an immune response by cationic lipids

5. Feb 27, 2024 Patent grant

   Vaccine compositions and methods of use

View all clinical trial activity →

• What is PDS Biotechnology?

  PDS Biotechnology is a biotech organization headquartered in Princeton, USA. It trades on NYSE under ticker PDSB. Primary therapeutic focus areas include Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, High-risk HPV Infection and Biopsy-proven CIN1. NovaPharmaNew

• Is PDS Biotechnology publicly traded?

  Yes. PDS Biotechnology is listed with ticker PDSB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does PDS Biotechnology develop or market?

  We link 5 drug profile(s) where PDS Biotechnology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pds-biotechnology-corp#company-drugs.

• What are the latest developments for PDS Biotechnology?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does PDS Biotechnology focus on?

  PDS Biotechnology focuses on Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, High-risk HPV Infection and Biopsy-proven CIN1 based on our analysis of their pipeline programs and drug development activities.